

## **Presentations by Rutgers Cancer Institute of New Jersey Faculty Members at the 2020 American Society of Hematology Annual Meeting & Exposition**

(\*\*All times noted are Pacific Standard Time)

### **Saturday, December 5, 2020**

7:00 am – 3:30 pm

#### **Genomic Ancestry in B Cell Lymphoid Malignancies (Session # 621)**

Presenting Author: Andrew M. Evens, DO, MMSc

Senior Author: Shridar Ganesan, MD, PhD

Program: [Poster](#)

#### **A Phase I-II Trial of DA-EPOCH-R Plus Ixazomib As Frontline Therapy for Patients with MYC-Aberrant Lymphoid Malignancies: The Daciphor Regimen (Session # 626)**

Author: Andrew M. Evens, DO, MMSc

Program: [Poster](#)

#### **A Phase I Dose Escalation Study of PT-112 in Patients with Relapsed or Refractory Multiple Myeloma (Session # 653)**

Author: Dennis Cooper, MD

Program: [Poster](#)

2:15 pm

#### **REGN5458, a BCMA x CD3 Bispecific Monoclonal Antibody, Induces Deep and Durable Responses in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) (Session # 653)**

Author: Dennis Cooper, MD

Program: [Oral](#)

3:15 pm

#### **Frequency and Prognostic Significance of Recurrent Gene Mutations in Pediatric B-ALL: Report from the DFCI ALL Consortium (Session # 612)**

Author: Peter D. Cole, MD

Program: [Oral](#)

### **Sunday, December 6, 2020**

7:00 am – 3:30 pm

#### **Prognostication for Advanced Stage Hodgkin Lymphoma (HL) in the Modern Era: A Project from the Hodgkin Lymphoma International Study for Individual Care (HoLISTIC) Consortium (Session # 624)**

Senior Author: Andrew M. Evens, DO, MMSc

Program: [Poster](#)

**Patient-Reported Outcomes Among Patients with High-Risk Untreated Follicular Lymphoma (FL) Randomized to Bendamustine/Rituximab (BR) or Bendamustine/Rituximab with Bortezomib (BVR) Therapy: Results from the ECOG-ACRIN E2408 Study (Session # 623)**

Author: Andrew M. Evens, DO, MMSc

Program: [Poster](#)

**Baseline Biomarkers of T-Cell Function Correlate with Clinical Responses to Odronextamab (REGN1979), and Loss of CD20 Target Antigen Expression Identified As a Mechanism of Treatment Resistance (Session # 626)**

Author: Rajat Bannerji, MD, PhD

Program: [Poster](#)

**Patient and Disease Factors Predict Risk of 1-Year Mortality Among Older Adults Who Receive Intensive Chemotherapy for Hodgkin Lymphoma (HL) (Session # 902)**

Author: Andrew M. Evens, DO, MMSc

Program: [Poster](#)

**Environmental Sars-Cov-2 Surface Testing: Low Incidence of Virus Positivity in Outpatient and Inpatient Hematology/Oncology Settings (Session # 901)**

Lead Author: Mansi Shah, MD

Senior Author: Andrew M. Evens, DO, MMSc

Authors: Imraan Jan, DO, Norma Belarmino, MHSA, Kara Saggiomo, MSN, Carolyn Hayes, RN, PhD, Deborah Toppmeyer, MD, Bruce Haffty, MD, Steven Libutti, MD

Program: [Poster](#)

**Final Report of Reduced Anthracycline Dose Intensity with the Addition of Dose Dense Rituximab in Children, Adolescents and Young Adults with De Novo Good Risk Mature B-Cell Non Hodgkin Lymphoma (B-NHL) (Session # 626)**

Author: Richard A. Drachtman, MD

Program: [Poster](#)

12:00 pm

**Odronextamab (REGN1979), a Human CD20 x CD3 Bispecific Antibody, Induces Durable, Complete Responses in Patients with Highly Refractory B-Cell Non-Hodgkin Lymphoma, Including Patients Refractory to CAR T Therapy (Session # 626)**

Presenting Author: Rajat Bannerji, MD, PhD

Program: [Oral](#)

2:00 pm

**Real World (RW) Outcomes and Prognostication of Older Patients with Primary Central Nervous System Lymphoma (PCNSL) in the Contemporary Era (Session # 627)**

Lead Author: Kevin David, MD

Senior Author: Andrew M. Evens, DO, MSc

Program: [Oral](#)

2:30 pm

**CNS Prophylaxis during Front-Line Therapy in Aggressive Non-Hodgkin Lymphomas: Real-World Outcomes and Practice Patterns from 19 US Academic Institutions (Session # 627)**

Author: Kevin A. David, MD

Program: [Oral](#)

**Monday, December 7, 2020**

7:00 am – 3:30 pm

**Reduction of Clostridium Difficile Infection in an Academic Medical Center Blood and Marrow Transplant Population (Session # 721)**

Authors: Anne A Tyno, RN, MSN, APN-C, Vimal Patel, MD,

Dale G. Schaar, MD, Roger Strair, MD, PhD

Senior Author: Dennis Cooper, MD

Program: [Poster](#)

**Radiation-Based Approaches as an Alternative to Stem Cell Transplant for Relapsed/Refractory Classical Hodgkin Lymphoma: A Multicenter Retrospective Analysis (Session # 624)**

Author: Andrew M. Evens, DO, MMSc

Program: [Poster](#)

**EBV-Positive Primary CNS Lymphomas in Older Patients: Incidence, Characteristics, Tumor Pathology, and Outcomes across a Large Multicenter Cohort (Session # 627)**

Authors: Kevin David, MD, Andrew M. Evens, DO, MMSc

Program: [Poster](#)

7:45 am

**Overcoming NOTCH1-Driven Chemoresistance in T-Cell Acute Lymphoblastic Leukemia Via Metabolic Intervention with Oxphos Inhibitor (Session # 605)**

Author: Daniel Herranz, PharmD. PhD

Program: [Oral](#)

9:30 am

**Polatuzumab Vedotin Plus Venetoclax with Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Primary Efficacy Analysis of a Phase Ib/II Study (Session # 626)**

Author: Rajat Bannerji, MD, PhD

Program: [Oral](#)

10:00 am

**Pegaspargase Re-Challenge after Grade 2 Hypersensitivity Reaction in Childhood Acute Lymphoblastic Leukemia: Results from DFCI 16-001 (Session # 612)**

Author: Peter D. Cole, MD

Program: [Oral](#)

1:30 pm

**The Burkitt Lymphoma International Prognostic Index (BL-IPI) (Session # 627)**

Senior Author: Andrew M. Evens, DO, MMSc

Program: [Oral](#)

1:45 pm

**Prognostication, Survival and Treatment-Related Outcomes in HIV-Associated Burkitt Lymphoma (HIV-BL): A US and UK Collaborative Analysis (Session # 627)**

Author: Andrew M. Evens, DO, MMSc

Program: [Oral](#)